therapeutics

Revance Therapeutics Shares Jumped After Positive Top-Line Results From Phase 3 Trial

Revance Therapeutics Shares Jumped After Positive Top-Line Results From Phase 3 Trial

Revance Therapeutics Inc (NASDAQ: RVNC) is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions. On Tuesday shares of the Revance jumped about 10% a after the company announced its n..

Insys co-founder Arrested on alleged Nationwide Opioid Scheme

Insys co-founder Arrested on alleged Nationwide Opioid Scheme

Co-Founder of Insys Therapeutics Inc. (NASDAQ: INSY) was arrested on Thursday by federal agents and charged with bribery, racketeering, and fraud to cause the illegal distribution of Fentanyl.John Kapoor was taken into custody in Phoenix, Arizona. K..

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics Stock Up After Partnership with Roche

Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock up more than 18% on Thursday after the biotechnology company announced that it has licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic t..

Sage Therapeutics Shares Down, Trial Did Not Meet the Primary Endpoint

Sage Therapeutics Shares Down, Trial Did Not Meet the Primary Endpoint

Sage Therapeutics (NASDAQ: SAGE) shares are down about 15% after the a clinical-stage biopharmaceutical company announced the results from the Phase 3 STATUS Trial of did not meet the primary endpoint. The trial of brexanolone (SAGE-547) in the trea..

Esperion Therapeutics Presented Positive Top-Level Results for Phase 2 of Trials

Esperion Therapeutics Presented Positive Top-Level Results for Phase 2 of Trials

Esperion Therapeutics Inc (NASDAQ: ESPR) announced positive top-level results for Phase 2 of trials for triplet oral therapy with bempedoic acid, ezetimibe and atorvastatin.The trials, which lasted six weeks, have yilded positive data as the LDL-C l..

Cara Therapeutic Shares Plummet

Cara Therapeutic Shares Plummet

Shares of Cara Therapeutic Inc. (NASDAQ: CARA) fell 31 percent on Friday after the company announced disappointing results on the CR845 oral medication from a phase 2b trial.Cara is a biopharmaceutical company that focuses on developing medications ..